<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04897763</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-2021-03</org_study_id>
    <nct_id>NCT04897763</nct_id>
  </id_info>
  <brief_title>Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)</brief_title>
  <acronym>PERTINENCE</acronym>
  <official_title>A Pilot Open-label, Feasibility Study to Assess safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ATONCO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250)&#xD;
      as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT radiopharmaceutical for the imaging&#xD;
      of Non-muscle-invasive bladder cancer (NMIBC) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a real need for treatment of NMIBC. Currently, treatment options include Bacillus&#xD;
      Calmette-Guerin (BCG) intravesical immunotherapy and mitomycin C chemotherapy. These&#xD;
      therapies are efficient for some time but relapses repeat them at more and more close&#xD;
      intervals and finally patients are refractory to them and require a radical cystectomy.&#xD;
&#xD;
      CAIX is expressed in 70% to 90% of bladder cancers but not in normal urothelial tissue. CAIX&#xD;
      is expressed on the membrane of Non-Muscle-Invasive Bladder Cancer cells.&#xD;
&#xD;
      Girentuximab, an anti-CAIX antibody could be a promising target in NMIBC. PET/CT with&#xD;
      Girentuximab labelled with 89Zirconium will be used for diagnosis purpose. 89Zr-Girentuximab&#xD;
      will be administered by intravesical instillation.&#xD;
&#xD;
      After establishing the targeting properties of 89Zr-Girentuximab PET/CT imaging tracer in&#xD;
      NMIBC, it should be interesting to develop a new targeted therapy using girentuximab-&#xD;
      radiolabelled with a therapeutic radionuclide such as Astatine-211 (211At-Girentuximab) in a&#xD;
      future clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Monocentric, open prospective study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PET/CT imaging 89Zr-girentuximab biodistribution assessment</measure>
    <time_frame>3 days</time_frame>
    <description>Standardized Uptake Values (SUVs) of bladder and whole body uptake will be evaluated by PET/CT imaging at T0, T0+2 hours, T0+20 hours and T0+44 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>89Zr-girentuximab Blood dosing</measure>
    <time_frame>2 days</time_frame>
    <description>89Zr-girentuximab activity dosing in blood will be measured (Becquerel/ml : Bq/ml) at T0+20 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the toxicity of 89Zr-girentuximab administered by intravesical instillation</measure>
    <time_frame>30 days</time_frame>
    <description>Number of adverse events due to intravesical administration of 89Zr-Girentuximab up to Day 30 after 89Zr-girentuximab administration. Adverse events will be assessed by using CTC-AE scale version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation protection management</measure>
    <time_frame>3 days</time_frame>
    <description>Radiation exposure of staff (extremities, lens and Whole body: µSv)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation protection management</measure>
    <time_frame>1 day</time_frame>
    <description>Radiopharmaceutical management from intravesical instillation to elimination (surfasic contamination: counts/cm2 or Bq/cm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the degree of CAIX expression by immunohistochemistry of the tumor</measure>
    <time_frame>3 months</time_frame>
    <description>The expression of CAIX will be assessed by immunohistochemistry in tumor sample from TransUrethral Resection of Bladder Tumor (TURBT) or cystectomy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>89Zr-TLX250 PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pretherapeutic 89Zr-TLX250 PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>89Zr-TLX250 PET/CT</intervention_name>
    <description>Pretherapeutic 89Zr-TLX250 PET/CT</description>
    <arm_group_label>89Zr-TLX250 PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained from the patient prior to performing any&#xD;
             protocol-related procedures, including screening evaluations.&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures.&#xD;
&#xD;
          -  Female or male, Age ≥ 18 years at time of study entry.&#xD;
&#xD;
          -  Performance Status: 0 or 1.&#xD;
&#xD;
          -  Clinical evidence of NMIBC based on cystoscopy and proven histologically of papillary&#xD;
             tumors.&#xD;
&#xD;
          -  Histologically-confirmed pTa Grade 3 or pT1 Grade 3 bladder cancer patients relapsing&#xD;
             without muscle invasion.&#xD;
&#xD;
          -  Negative sterile Urine cytobacteriological testing at baseline (T0).&#xD;
&#xD;
          -  Consent to use a contraception method for at least 30 days after administration of&#xD;
             89Zr-girentuximab.&#xD;
&#xD;
          -  Patient has valid health insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with urinary incontinence.&#xD;
&#xD;
          -  Known hypersensitivity to girentuximab.&#xD;
&#xD;
          -  Exposure to any experimental diagnostic or therapeutic drug within 30 days prior the&#xD;
             date of planned administration of 89Zr-girentuximab&#xD;
&#xD;
          -  Exposure to any radiopharmaceutical within 30 days (corresponding to 10 half-lives of&#xD;
             Zr-89) prior to the administration of 89Zr-girentuximab&#xD;
&#xD;
          -  Patients suffering from a bladder cancer at stage pT2, pT3 or pT4&#xD;
&#xD;
          -  Serious non-malignant disease that may interfere with the objectives of the study or&#xD;
             with the safety or compliance of the patient; as judged by the investigator&#xD;
&#xD;
          -  Concomitant cancer in the past 5 years except cutaneous cancers (except melanoma) and&#xD;
             in situ carcinoma&#xD;
&#xD;
          -  Prior chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy),&#xD;
             immunotherapy within 21 days of 89Zr-girentuximab administration&#xD;
&#xD;
          -  Patients with known human immunodeficiency viruses (HIV), Hepatitis B virus (HBV) and&#xD;
             Hepatitis C Virus (HCV) infections,&#xD;
&#xD;
          -  Pregnant or likely to be pregnant or nursing patient.&#xD;
&#xD;
          -  Mental impairment that may compromise the ability to give informed consent and comply&#xD;
             with the requirements of the study&#xD;
&#xD;
          -  Persons deprived of their liberty, under a measure of safeguard of justice, under&#xD;
             guardianship or placed under the authority of a guardian.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline ROUSSEAU, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut de Cancerologie de l'Ousest - ICO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline ROUSSEAU, MD, PhD</last_name>
    <phone>+ 33 240679931</phone>
    <email>caroline.rousseau@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia ALLAM, PhD</last_name>
    <phone>+33 240679826</phone>
    <email>nadia.allam@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de cancerologie de l'Ouest</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline ROUSSEAU, MD, PhD</last_name>
      <phone>+33240679931</phone>
      <email>caroline.rousseau@ico.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-muscle-invasive bladder cancer (NMIBC) patients</keyword>
  <keyword>89Zr-Girentuximab ((89Zirconium-Girentuximab) PET/CT</keyword>
  <keyword>Safety assessment</keyword>
  <keyword>pilot study</keyword>
  <keyword>feasibility study</keyword>
  <keyword>89Zr-TLX250 (89Zirconium-TLX250) PET/CT</keyword>
  <keyword>Positron Emission Tomography/Computerized Tomography (PET/CT) scan</keyword>
  <keyword>carbonic anhydrase IX (CAIX)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

